Precision BioSciences to Report First Quarter Results on May 13, 2024

Rhea-AI Summary

Precision BioSciences, Inc. (Nasdaq: DTIL) will report its first-quarter financial results on May 13, 2024. The company utilizes its ARCUS® platform for gene editing therapies, including elimination, insertion, and excision.

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507972330/en/

Investor and Media Contact:

Naresh Tanna

Vice President of Investor Relations

naresh.tanna@precisionbiosciences.com

Source: Precision BioSciences, Inc.

FAQ

When will Precision BioSciences report its first-quarter results?

Precision BioSciences will report its first-quarter financial results on May 13, 2024.

What is Precision BioSciences' stock symbol?

Precision BioSciences' stock symbol is DTIL.

What platform does Precision BioSciences use for gene editing therapies?

Precision BioSciences utilizes its ARCUS® platform for gene editing therapies, including gene elimination, insertion, and excision.

What type of gene editing does Precision BioSciences focus on?

Precision BioSciences focuses on in vivo gene editing therapies for sophisticated gene edits.

When will Precision BioSciences provide a business update?

Precision BioSciences will provide a business update on Monday, May 13, 2024.